Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ocifisertib hydrochloride (CFI-400945 hydrochloride) is the hydrochloride salt form of Ocifisertib. It is an orally bioavailable PLK4 inhibitor with a Ki of 0.26 nM and an IC50 of 2.8 nM. This compound inhibits the growth of multiple cancer cell types, causes cell cycle arrest at the G2/M phase, and induces apoptosis. In mouse models, Ocifisertib hydrochloride exhibits antitumor activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | Ocifisertib hydrochloride (CFI-400945 hydrochloride) is the hydrochloride salt form of Ocifisertib. It is an orally bioavailable PLK4 inhibitor with a Ki of 0.26 nM and an IC50 of 2.8 nM. This compound inhibits the growth of multiple cancer cell types, causes cell cycle arrest at the G2/M phase, and induces apoptosis. In mouse models, Ocifisertib hydrochloride exhibits antitumor activity. |
Targets&IC50 | AURKA:140 nM, PLK4:2.8 nM, TRKB:9 nM, TIE2/TEK:22 nM, TRKA:6 nM, AURKB/INCENP:98 nM |
Alias | CFI-400945 hydrochloride |
Molecular Weight | 571.11 |
Formula | C33H35ClN4O3 |
Cas No. | 1338799-83-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.